Opposite effect of ERK1/2 and JNK on p53-independent p21 WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity

Journal of Biomedical Science

Volumn 13, Issue 1, 2006, Pages 113-125

  Huang, Huei Sheng ^a   Liu, Zi Miao ^a   Ding, Ling ^a   Chang, Wen Chang ^a   Hsu, Pei Yin ^a   Wang, Shu Hui ^b   Chi, Ching Chi ^b   Chuang, Cheng Hsin ^c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

Author keywords

Arsenic trioxide; ERK1 2; JNK; p21WAF1 CIP1

Indexed keywords

ARSENIC TRIOXIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN P53; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS REGULATION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; ARSENICALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OXIDES; RAF KINASES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 31544434922     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-005-9040-z     Document Type: Article

References (34)

1. Bagla P. and Kaiser J., India's spreading health crisis draws global arsenic experts. Science 274: 174-175, 1996.
2. Miller W.H. Jr., Schipper H.M., Lee J.S. and Singer JWaxman S., Mechanisms of action of arsenic trioxide. Cancer Res. 62: 3893-3903, 2002.
3. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88: 1052-1061, 1996.
4. Wang T.S., Kuo C.F., Jan K.Y. and Huang H., Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J. Cell Physiol. 169: 256-268, 1996.
5. Murgo A.J., Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 6(Suppl 2): 22-28, 2001.
6. Sherr C.J. and Roberts J.M., CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13: 1501-1512, 1999.
7. Jacks T. and Weinberg R.A., Cell-cycle control and its watchman. Nature 381: 643-644, 1996.
8. Harper J.W., Adami G.R., Wei N., Keyomarsi K. and Elledge S.J., The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
9. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W. and Vogelstein B., WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
10. Guadagno T.M. and Newport J.W., Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell 84: 73-82, 1996.
11. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., Fattaey A. and Harlow E., New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11: 847-862, 1997.
12. Haffner R. and Oren M., Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev. 5: 84-90, 1995.
13. Michieli P., Chedid M., Lin D., Pierce J.H., Mercer W.E. and Givol D., Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54: 3391-3395, 1994.
14. Russo T., Zambrano N., Esposito F., Ammendola R., Cimino F., Fiscella M., Jackman J., O'Connor P.M., Anderson C.W. and Appella E., A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J. Biol. Chem. 270: 29386-29391, 1995.
15. Chen F. and Shi X., Intracellular signal transduction of cells in response to carcinogenic metals. Crit. Rev. Oncol. Hematol. 42: 105-121, 2002.
16. Yih L.H. and Lee T.C., Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res. 60: 6346-6352, 2000.
17. Yih L.H. and Lee T.C., Induction of C-anaphase and diplochromosome through dysregulation of spindle assembly checkpoint by sodium arsenite in human fibroblasts. Cancer Res. 63: 6680-6688, 2003.
18. Ling Y.H., Jiang J.D., Holland J.F. and Perez-Soler R., Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol. Pharmacol. 62: 529-538, 2002.
19. Garrington T.P. and Johnson G.L., Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. 11: 211-218, 1999.
20. Cavigelli M., Li W.W., Lin A., Su B., Yoshioka K. and Karin M., The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 15: 6269-6279, 1996.
21. Liu Y., Guyton K.Z., Gorospe M., Xu Q., Lee J.C. and Holbrook N.J., Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radic. Biol. Med. 21: 771-781, 1996.
22. Chen W., Martindale J.L., Holbrook N.J. and Liu Y., Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and She. Mol. Cell Biol. 18: 5178-5188, 1998.
23. Kwok T.T., Mok C.H. and Menton-Brennan L., Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res. 54: 2834-2836, 1994.
24. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H. and Boyd M.R., Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48: 589-601, 1988.
25. Huang H.S., Chang W.C. and Chen C.J., Involvement of reactive oxygen species in arsenite-induced downregulation of phospholipid hydroperoxide glutathione peroxidase in human epidermoid carcinoma A431 cells. Free Radic. Biol. Med. 33: 864-873, 2002.
26. Agarwal M.L., Taylor W.R., Chernov M.V., Chernova O.B. and Stark G.R., The p53 network. J. Biol. Chem. 273: 1-4, 1998.
27. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88: 1052-1061, 1996.
28. Bode A.M. and Dong Z., The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 42: 5-24, 2002.
29. Kim J.Y., Choi J.A., Kim T.H., Yoo Y.D., Kim J.I., Lee Y.J., Yoo S.Y., Cho C.K., Lee Y.S. and Lee S.J., Involvement of p38 mitogen-activated protein kinase in the cell growth inhibition by sodium arsenite. J. Cell. Physiol. 190: 29-37, 2002.
30. Johannessen L.E., Knardal S.L. and Madshus I.H., Epidermal growth factor increases the level of the cyclin-dependent kinase (CDK) inhibitor p21/CIP1 (CDK-interacting protein 1) in A431 cells by increasing the half-lives of the p21/CIP1 transcript and the p21/CIP1 protein. Biochem. J. 337(Pt 3): 599-606, 1999.
31. Shen Y.H., Godlewski J., Zhu J., Sathyanarayana P., Leaner V., Birrer M.J., Rana A. and Tzivion G., Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J. Biol. Chem. 278: 26715-26721, 2003.
32. Park W.H.. Seol J.G., Kim E.S., Hyun J.M., Jung C.W., Lee C.C., Kim B.K. and Lee Y.Y., Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 60: 3065-3071, 2000.
33. Jiang X.H., Wong B.C., Yuen S.T., Jiang S.H., Cho C.H., Lai K.C., Lin M.C., Kung H.F. and Lam S.K., Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int. J. Cancer 91: 173-179, 2001.
34. Kip1. J. Clin. Invest. 103: 597-604, 1999.